Why the study?
Does bradykinin or ACE-I improve cardiac biomarkers and outcomes in patients undergoing surgery or coronary intervention?
Population
8 RCTs totaling 268 patients undergoing surgery or coronary intervention
Comparison
Bradykinin or angiotensin converting enzyme… vs Control groups
Design
Systematic_review
Authors
Loading...
May support perioperative ACE-I use for myocardial protection; confirms kinin pathway benefits on biomarkers in procedural settings.
Does bradykinin or ACE-I improve cardiac biomarkers and outcomes in patients undergoing surgery or coronary intervention?
Bradykinin and ACE-I appear to offer myocardial protection during cardiovascular interventions by reducing cardiac biomarkers and infarct size, though optimal dosing requires further study.
Tabary et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: